FDA stability – Page 17

Stability Study Design Errors in Biologics and Biosimilar Products

Understanding and Addressing Stability Study Design Errors in Biologics and Biosimilar Products Stability study design errors can lead to significant consequences in the pharmaceutical industry, especially for biologics and biosimilars.…

How to Avoid Deficiency Letters Related to Stability Study Design

How to Prevent Deficiency Letters in Stability Study Design In the highly regulated pharmaceutical landscape, organizations are often faced with rigorous scrutiny regarding stability studies. A deficiency letter can halt…

How to Prevent Stability Data Integrity Issues During Study Design

Mitigating Issues Related to Stability Study Design In the landscape of pharmaceutical manufacturing, integrity issues during stability study design can lead to significant regulatory scrutiny and jeopardize product approvals. This…

Regulatory Expectations for Stability Data Integrity and Audit Trails

Addressing Challenges with Data Integrity in Stability Studies: Ensuring Compliance with Regulatory Expectations In the pharmaceutical industry, maintaining the integrity of stability data is critical for ensuring compliance with regulatory…

Stability Protocol Gaps in Post-Approval Change Submissions

Addressing Gaps in Stability Study Design for Post-Approval Changes In the dynamic landscape of pharmaceutical development, maintaining the integrity of stability studies after a product’s market approval can be challenging.…

How to Support Drug Product Expiry with Statistical Stability Data

Implementing Statistical Stability Data to Support Drug Product Expiry In the pharmaceutical industry, ensuring drug product efficacy throughout its shelf life is paramount. One of the critical activities in achieving…

Why Annual Stability Batches Fail to Prove Continued Control

Addressing Failures in Annual Stability Batches and Maintaining Control The pharmaceutical manufacturing industry faces numerous challenges in ensuring the reliability and accuracy of stability studies. One common but critical issue…

Regulatory Expectations for Retest Periods of APIs

Addressing Challenges in Complying with Regulatory Expectations for Retest Periods of APIs The requirement for establishing stability profiles for Active Pharmaceutical Ingredients (APIs) can often lead to challenges in maintaining…

Stability Study Design Mistakes in Ongoing Stability Programs

Common Pitfalls in Stability Study Design and Effective Solutions In the high-stakes world of pharmaceutical development, the integrity of stability studies is paramount. Stability study design errors can have cascading…

Stability Study Design Mistakes in Ongoing Stability Programs

Common Pitfalls in Stability Study Design within Ongoing Stability Programs Stability study design errors can significantly impact the integrity of data supporting a pharmaceutical product’s shelf life. As professionals working…

How to Prepare Stability Justification for ASEAN and Emerging Markets

Preparing Effective Stability Justification for Emerging Markets Navigating the regulatory expectations for stability studies is crucial for pharmaceutical manufacturers, especially when preparing to enter ASEAN and other emerging markets. Understanding…

How Poor Statistical Planning Affects Shelf-Life Assignment

Understanding the Impact of Inadequate Statistical Planning on Shelf-Life Assignment In the highly regulated field of pharmaceutical manufacturing, precision in stability studies is critical. However, errors stemming from poor statistical…